Skip to main content
. 2018 Feb 5;20(9):1231–1239. doi: 10.1093/neuonc/noy015

Table 2.

Adverse events* for patients treated with Evo/Bev

Adverse Event Total Grade 3/4
Rash 11 (47.8%) 1 (4.3%)
Anal inflammation 4 (17.4%) 2 (8.7%)
Fatigue 4 (17.4%) 2 (8.7%)
Proctitis 4 (17.4%) 2 (8.7%)
Nausea 4 (17.4%) 1 (4.3%)
Stomatitis 4 (17.4%) 0 (0.0%)
Thrombocytopenia 3 (13.0%) 1 (4.3%)

*By Common Terminology Criteria for Adverse Events 4.0.